J&J seeks authorization for COVID-19 vaccine booster
Johnson & Johnson today announced its request that the Food and Drug Administration amend the current emergency use authorization for the J&J COVID-19 vaccine to include a booster dose. J&J’s submission includes phase 3 U.S. clinical trial data that affirms the booster’s effectiveness; when administered 56 days following a primary dose, J&J said, a booster provided 94% protection against symptomatic (moderate to severe/critical) COVID-19 and 100% protection against severe/critical COVID-19, at least 14 days after booster administration. The submission also includes phase 1/2a data on boosters’ effectiveness at the six-month juncture. The FDA later this month will meet to consider booster for J&J and Moderna.
Related News Articles
Headline
Adults age 65 and older are encouraged to receive an updated dosage of the COVID-19 vaccine, the Centers for Disease Control and Prevention announced April 25…
Headline
The Pfizer and Moderna COVID-19 vaccines can cause myocarditis, but do not appear to cause infertility, Guillain-Barré syndrome, Bell’s palsy, thrombosis with…
Headline
Centers for Disease Control and Prevention Director Mandy Cohen, M.D., Feb. 28 endorsed a recommendation by its Advisory Committee on Immunization Practices…
Headline
A CDC study released Dec. 21 found low COVID-19 and flu vaccination coverage for most adults, and low RSV vaccination coverage for adults aged 60 and…
Headline
Fewer than one in four health care professionals working in acute care hospitals and nursing homes were up to date with COVID-19 vaccination during the 2022-23…
Headline
Children under age 12 should receive a 0.25 milliliter dose of the 2023-24 Moderna COVID-19 vaccine, not the full vial for that age group, the Food and Drug…